Skip to content

Efficacy of Higher vs. Lower Doses of Dexamethasone in Patients With Acute Hypoxemic Respiratory Failure (Including ARDS) Caused by Infections (Including COVID-19)

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519759-27-00
Acronym
DEXA-REFINE-COVID-19
Enrollment
980
Registered
2024-12-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Hypoxemic Respiratory Failure

Brief summary

All-cause hospital mortality.

Detailed description

Number of ventilator free-days (VFDs) at Day 28 (defined as days alive and free from mechanical ventilation at day 28 after intubation. For subjects ventilated >=28 days and for subjects who die, VFD is 0., Mortality at ICU and at Day 28., Duration (in days) on mechanical ventilation., Length of stay (in days) in the hospital for survivors., Time (in days) from treatment initiation to death., Proportions with viral RNA detection over time.

Interventions

DRUGDexametasona Kern Pharma 7
DRUG2 mg solución inyectable

Sponsors

Consorcio Centro De Investigacion Biomedica En Red
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
All-cause hospital mortality.

Secondary

MeasureTime frame
Number of ventilator free-days (VFDs) at Day 28 (defined as days alive and free from mechanical ventilation at day 28 after intubation. For subjects ventilated >=28 days and for subjects who die, VFD is 0., Mortality at ICU and at Day 28., Duration (in days) on mechanical ventilation., Length of stay (in days) in the hospital for survivors., Time (in days) from treatment initiation to death., Proportions with viral RNA detection over time.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026